Hemogenyx Pharmaceuticals PLC announces Corporate Presentation
Hemogenyx Pharmaceuticals has released a new corporate presentation detailing its work in developing innovative therapies for deadly blood diseases. The company, based in London with operations in New York City, focuses on advancing treatments for conditions like leukemia, lymphoma, and severe autoimmune diseases. With over 50 years of experience in bone marrow transplantation, Hemogenyx aims to improve patient outcomes and broaden access to these life-saving procedures. The presentation can be accessed here.
- Hemogenyx is developing innovative therapies for blood-related diseases, potentially increasing treatment options for patients.
- The company is focused on broadening access to bone marrow transplantation for life-threatening diseases.
- None.
LONDON, UK / ACCESSWIRE / July 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce that a new corporate presentation is available at http://www.rns-pdf.londonstockexchange.com/rns/0316E_1-2021-7-2.pdf.
Enquiries:
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
Peter Redmond, Director | peter.redmond@hemogenyx.com |
| |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/654028/Hemogenyx-Pharmaceuticals-PLC-announces-Corporate-Presentation
FAQ
What is the latest update from Hemogenyx Pharmaceuticals?
Where can I find the corporate presentation of Hemogenyx Pharmaceuticals?
What diseases does Hemogenyx Pharmaceuticals focus on?
What is the significance of Hemogenyx Pharmaceuticals' work?
